<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An announcement from Gossamer Bio ( (GOSS) ) is now available. On May 18, 2026, Gossamer Bio said it had entered a transaction support agreement with holders of about 75.2% of its 5.00% convertible senior notes due 2027, backing a complex exchange offer that would swap the existing notes into equity, new 7.50% senior secured first-lien convertible notes due 2030 and warrants, with a 98% minimum participation condition that can be waived. The deal, which includes tight transfer restrictions, mutual releases, detailed termination rights and voting agreements on new shares, is designed to cut convertible debt from $200 million to about $72 million, extend maturities and strengthen the balance sheet ahead of pivotal regulatory and commercial milestones. The company also secured an in-person Pre-NDA Type B meeting with the U.S. Food and Drug Administration in mid-June 2026 and plans, subject to that meeting, to file a New Drug Application for seralutinib in pulmonary arterial hypertension in September 2026, targeting a potential FDA decision in the third quarter of 2027 and pre-launch activities that year. Gossamer reported exploratory Phase 3 PROSERA CT functional respiratory imaging data showing statistically significant structural changes across arterial, venous and fibrotic compartments that correlated with clinical improvements, and its board approved a restated 2019 equity incentive plan that would materially expand the share reserve—subject to both the exchange offer closing and shareholder approval—potentially increasing dilution but aligning incentives as the company moves toward a possible first commercial product. The most recent analyst rating on (GOSS) stock is a Sell with a $0.30 price target. To see the full list of analyst forecasts on Gossamer Bio stock, see the GOSS Stock Forecast page. Spark’s Take on GOSS Stock According to Spark, TipRanks’ AI Analyst, GOSS is a Neutral. The score is weighed down primarily by weak financial performance (large losses, heavy cash burn, and negative equity), reinforced by bearish technical signals. Corporate events add meaningful downside risk (Nasdaq compliance issue and mixed Phase 3 outcome), while valuation provides limited support given negative earnings and no dividend data. To see Spark’s full report on GOSS stock, click here. More about Gossamer Bio Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing the inhaled PDGFR, CSF1R and c-KIT inhibitor seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company collaborates globally with the Chiesi Group and reported cash, cash equivalents and marketable securities of $99 million as of March 31, 2026. Average Trading Volume: 16,021,384 Technical Sentiment Signal: Sell Current Market Cap: $79.8M For a thorough assessment of GOSS stock, go to TipRanks’ Stock Analysis page.</div>

GOSS

SBIO

Gossamer Bio has restructured its debt by entering a transaction support agreement with holders of 75.2% of its convertible senior notes, reducing debt from $200 million to approximately $72 million. The company plans to file a New Drug Application for seralutinib in September 2026, targeting FDA approval by Q3 2027. Despite a recent analyst rating of Sell with a $0.30 price target, Gossamer aims to strengthen its balance sheet and align incentives as it approaches potential commercialization.

Gossamer Bio Restructures Debt and Advances Seralutinib Program